<DOC>
	<DOCNO>NCT01409070</DOCNO>
	<brief_summary>In Myelodysplastic syndrome , epigenetic treatment Azacitidine Decitabine highlight phase 3 study . However , 1st line treatment , evaluate head head comparison two drug . This study retrospective study compare efficacy two drug .</brief_summary>
	<brief_title>Head Head Comparison Azacitidine Decitabine Myelodysplastic Syndrome</brief_title>
	<detailed_description>Among 300 MDS patient , 200 take Azacitidine 100 take Decitabine . Medical chart patient review assess efficacy safety two agent .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Confirmed MDS bone marrow examination Receiving azacitidine decitabine first line chemotherapy Adequate hepatic , cardiac , renal function Previously treat another anticancer therapy due MDS Not available clinical information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>MDS</keyword>
</DOC>